Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Precision Red Fluores...

    2025-10-30

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP): Precision Red Fluorescent Reporter Gene mRNA

    Executive Summary: EZ Cap™ mCherry mRNA (5mCTP, ψUTP) delivers a 996-nucleotide synthetic mRNA encoding mCherry, a monomeric red fluorescent protein. Cap 1 enzymatic capping and 5mCTP/ψUTP nucleotide modifications suppress innate immune responses and prolong mRNA stability in vitro and in vivo (ApexBio, Product Page). The mRNA is formulated at ~1 mg/mL in 1 mM sodium citrate buffer, pH 6.4, and includes a poly(A) tail for enhanced translation. This design allows high-fidelity fluorescent reporting, minimizes cellular toxicity, and enables robust performance in nanoparticle delivery platforms (Roach 2024, Pace Univ). The product is suitable for molecular tracking, localization studies, and benchmarking of advanced delivery systems.

    Biological Rationale

    Messenger RNA (mRNA) reporter systems are essential for visualizing gene expression and protein localization in living cells. mCherry is a red fluorescent protein derived from Discosoma spp., emitting at a peak wavelength of 610 nm. Its monomeric structure (ApexBio) provides minimal aggregation in mammalian cells, making it suitable for precise molecular imaging. Synthetic mRNAs with Cap 1 structures and nucleotide modifications such as 5-methylcytidine (5mCTP) and pseudouridine (ψUTP) mimic mammalian mRNAs and evade pattern recognition receptors, reducing type I interferon response (From Mechanism to Milestone). This configuration addresses the limitations of unmodified reporter mRNAs, such as rapid degradation and immune activation.

    Mechanism of Action of EZ Cap™ mCherry mRNA (5mCTP, ψUTP)

    • Cap 1 Structure: The 5'-cap (m7GpppNmp, where N is any nucleotide, and m is a 2'-O-methyl group) is added enzymatically using Vaccinia virus Capping Enzyme, GTP, S-adenosylmethionine, and 2'-O-Methyltransferase. This structure increases translation efficiency and reduces detection by innate immune sensors (EZ Cap™ mCherry mRNA: Redefining Reporter Gene Fluorescence).
    • 5mCTP & ψUTP: Incorporation of 5-methylcytidine triphosphate and pseudouridine triphosphate reduces activation of toll-like receptors (TLR3, TLR7, TLR8) and RNA sensors such as RIG-I, minimizing interferon signaling and increasing mRNA stability (Redefining Reporter Gene mRNA).
    • Poly(A) Tail: The addition of a polyadenylated tail (commonly >100 adenines) enhances recruitment of poly(A)-binding proteins and translation initiation complexes, further boosting protein expression.

    These features collectively extend the mRNA's half-life and translation window, enabling reliable and sustained reporter signal for cell tracking, localization, and functional studies.

    Evidence & Benchmarks

    • EZ Cap™ mCherry mRNA (5mCTP, ψUTP) demonstrates suppressed innate immune activation relative to unmodified mRNA, as evidenced by reduced type I interferon production in human cell assays (Roach 2024, Table 3).
    • mCherry mRNA with Cap 1 capping sustains detectable fluorescence for >48 hours post-transfection in mammalian cells, outperforming uncapped or Cap 0 mRNAs (EZ Cap™ mCherry mRNA: Red Fluorescent Reporter).
    • 5mCTP/ψUTP-modified mRNA resists RNase-mediated degradation in serum-containing media for at least 6 hours at 37°C (Roach 2024, Methods section).
    • Mesoscale nanoparticle delivery of modified mCherry mRNA enables >90% transfection efficiency in HEK293 cells with minimal cytotoxicity (viability >95%) (Redefining Reporter Gene Fluorescence).
    • mCherry is approximately 236 amino acids in length and the mRNA is 996 nucleotides, allowing for efficient translation and robust fluorescence at 610 nm (ApexBio).

    Applications, Limits & Misconceptions

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP) is optimized for use as a molecular reporter in live cell imaging, localization studies, nanoparticle delivery validation, and as a benchmarking tool for mRNA stability and expression (Product page). Its robust fluorescence and low immunogenicity make it preferable over green or yellow reporters in multiplexed assays.

    Common Pitfalls or Misconceptions

    • Not suitable for in vivo clinical therapy. This product is for research use only and is not validated for therapeutic applications.
    • Does not circumvent all immune responses. While 5mCTP/ψUTP reduce innate immune activation, extremely high mRNA doses or certain cell types may still mount responses.
    • Requires cold-chain storage. The product should be stored at or below -40°C to maintain integrity; improper storage reduces activity.
    • Reporter specificity. mCherry fluorescence may overlap with other red fluorophores; spectral imaging controls should be used for multiplex experiments.
    • Transfection efficiency is context-dependent. Results may vary by cell line and delivery method; optimization is recommended for each experimental setup.

    Workflow Integration & Parameters

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP) can be directly incorporated into standard transfection workflows using lipid-based, polymeric, or mesoscale nanoparticle carriers. The mRNA is supplied at ~1 mg/mL in 1 mM sodium citrate, pH 6.4, ready for dilution. For in vitro applications, 100–500 ng/well (24-well plate) is typical, but optimization is advised. The Cap 1 structure ensures compatibility with mammalian translation machinery. The inclusion of 5mCTP and ψUTP allows parallel benchmarking against non-modified controls for mRNA stability and immune activation. This article expands upon the mechanistic insights discussed in Next-Generation Reporter Gene Strategies by providing specific workflow integration details and experimental parameters. For broader discussion of benchmarking strategies, see Redefining Reporter Gene mRNA.

    Conclusion & Outlook

    EZ Cap™ mCherry mRNA (5mCTP, ψUTP) sets a new standard for red fluorescent reporter gene mRNA, combining advanced capping and nucleotide modifications for optimal expression and minimal immunogenicity in research settings. Future developments may include further chemical modifications or tailored delivery systems for enhanced in vivo applications. For the latest product details and ordering, visit the EZ Cap™ mCherry mRNA (5mCTP, ψUTP) product page.